ECSP21000308A - Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones - Google Patents

Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones

Info

Publication number
ECSP21000308A
ECSP21000308A ECSENADI2021308A ECDI202100308A ECSP21000308A EC SP21000308 A ECSP21000308 A EC SP21000308A EC SENADI2021308 A ECSENADI2021308 A EC SENADI2021308A EC DI202100308 A ECDI202100308 A EC DI202100308A EC SP21000308 A ECSP21000308 A EC SP21000308A
Authority
EC
Ecuador
Prior art keywords
aquaculture
applications
antibodies against
against pathogenic
pathogenic agents
Prior art date
Application number
ECSENADI2021308A
Other languages
English (en)
Inventor
Petegem Filip Louis Van
Tsz Ying Cheung
Slade Loutet
Hamlet Abnousi
Original Assignee
Novobind Livestock Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novobind Livestock Therapeutics Inc filed Critical Novobind Livestock Therapeutics Inc
Publication of ECSP21000308A publication Critical patent/ECSP21000308A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1239—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Vibrionaceae (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Feed For Specific Animals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se describen aquí los métodos y anticuerpos efectivos para reducir, eliminar o prevenir la infección de una población bacteriana o viral en un animal acuático. También se describen aquí los antígenos efectivos para reducir una población bacteriana o viral en un animal acuático empleando anticuerpos de cadena pesada y fragmentos de VHH.
ECSENADI2021308A 2018-06-05 2021-01-05 Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones ECSP21000308A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862680736P 2018-06-05 2018-06-05

Publications (1)

Publication Number Publication Date
ECSP21000308A true ECSP21000308A (es) 2021-06-30

Family

ID=69059691

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI2021308A ECSP21000308A (es) 2018-06-05 2021-01-05 Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones

Country Status (9)

Country Link
US (1) US20220119506A1 (es)
EP (1) EP3802592A4 (es)
CN (1) CN112566932A (es)
BR (1) BR112020024878A2 (es)
CA (1) CA3102039A1 (es)
EC (1) ECSP21000308A (es)
IL (1) IL279117A (es)
MX (1) MX2020013248A (es)
WO (1) WO2020008254A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017199094A1 (en) 2016-05-20 2017-11-23 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof
WO2021046401A1 (en) * 2019-09-05 2021-03-11 Pebble Labs Usa, Inc. Systems, methods, and compositions for the inhibition of bacterial toxins to treat early mortality syndrome in aquatic animals
KR102550527B1 (ko) * 2020-11-27 2023-07-03 주식회사 엔바이로젠 흰반점증후군 바이러스에 특이적인 재조합 항체 및 이의 용도
CN115181731B (zh) * 2021-04-02 2023-12-15 青岛诺安百特生物技术有限公司 一株坎贝氏弧菌噬菌体、制备方法及其应用
WO2023104933A1 (en) * 2021-12-07 2023-06-15 new/era/mabs GmbH Camelid antibodies for use in therapy and diagnosis
WO2024092360A1 (en) * 2022-11-03 2024-05-10 Novobind Livestock Therapeutics Inc. Antibodies against aquaculture disease-causing agents and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG144692A1 (en) * 2000-09-15 2008-08-28 Intervet Int Bv Antigenic proteins of shrimp white spot syndrome virus and uses thereof
KR20030069506A (ko) * 2002-02-21 2003-08-27 주식회사 리앤조바이오텍 새우 흰 반점 바이러스에 대한 난황항체
ES2655912T3 (es) * 2002-11-08 2018-02-22 Ablynx N.V. Anticuerpos de dominio simple dirigidos contra factor de necrosis tumoral-alfa y usos para los mismos
TW200738750A (en) * 2005-12-06 2007-10-16 Domantis Ltd Ligands and methods of use therefor
WO2010030182A2 (en) * 2008-09-10 2010-03-18 Bac Ip B.V. Antigen-binding proteins that inhibit superantigens for the treatment of skin diseases
CN101691403B (zh) * 2009-08-03 2011-11-09 中国海洋大学 抗对虾白斑症病毒囊膜蛋白vp28独特型单克隆抗体及其制备方法
DE102011121238A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-antikörper gegen clostridium difficile toxine
WO2015145250A2 (en) * 2014-03-27 2015-10-01 Ghosh Sambuddha Expression of a single chain antibody against salmonella in lactobacillus
WO2017199094A1 (en) * 2016-05-20 2017-11-23 Novobind Livestock Therapeutics Inc. Antibodies against microorganisms and uses thereof

Also Published As

Publication number Publication date
CN112566932A (zh) 2021-03-26
BR112020024878A2 (pt) 2021-03-09
EP3802592A4 (en) 2022-06-15
US20220119506A1 (en) 2022-04-21
CA3102039A1 (en) 2020-01-09
EP3802592A1 (en) 2021-04-14
MX2020013248A (es) 2021-04-13
IL279117A (en) 2021-01-31
WO2020008254A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
ECSP21000308A (es) Anticuerpos contra agentes patógenos en acuacultura y sus aplicaciones
PH12021550025A1 (en) Antibodies against disease causing agents of poultry and uses thereof
UY38215A (es) Métodos y composiciones para matar una bacteria de interés
ECSP21000695A (es) Anticuerpos dirigidos contra il-11
CY1122179T1 (el) Μεθοδοι και συνθεσεις για την παραγωγη ή την διατηρηση πολυδυναμων κυτταρων
EA201791554A1 (ru) Биспецифичные антитела против cd3 и cd20
CL2017002433A1 (es) Una nueva forma de il33, formas mutadas de il33, anticuerpos, ensayos y métodos para usar los mismos
CR20170139A (es) Proteínas de fusión, bacterias recombinantes y métodos de uso de las bacterias recombinantes
CL2019002626A1 (es) Anticuerpos anti-par2 y usos de los mismos.
EA201892568A1 (ru) Способы получения контрастных средств для ультразвукового исследования
EA201992278A1 (ru) Способы и композиции для снижения иммуногенности
BR112021023296A2 (pt) Anticorpos contra agentes causaudores de doenças de aves e usos dos mesmos
ECSP20016817A (es) Sistemas y métodos para el control de la enfermedad de necrosis hepatopancreática aguda
CL2019000664A1 (es) Sistema paratransgénico novedoso para el control de mosquitos que transmiten enfermedades.
CY1125009T1 (el) Προβιοτικα βακτηριδια για ιχθεις
CL2019001275A1 (es) Atenuación de virulencia bacteriana mediante atenuación de transporte de folato bacteriano.
AR105541A1 (es) ANTICUERPOS MONOCLONALES ESPECÍFICOS PARA EL ANTÍGENO P DEL VIRUS RESPIRATORIO SINCICIAL HUMANO (VRSh), PRODUCIDOS Y SECRETADOS POR HIBRIDOMAS CELULARES, ÚTILES PARA LA DETECCIÓN Y EL DIAGNÓSTICO DE LA INFECCIÓN CAUSADA POR VRSh
CO2020006907A2 (es) Péptidos antimicrobianos y métodos para usarlos
ECSP21068097A (es) Anticuerpos claudina 6 y usos de los mismos
EA202192923A1 (ru) Антитела и способы лечения инфекции, вызываемой вирусом гриппа а
CL2020001816A1 (es) Bacterias probióticas para peces.
CL2020003168A1 (es) Métodos de uso de cd24 para prevenir y tratar la enfermedad de injerto contra huésped y la mucositis
CL2021002866A1 (es) Tratamiento de la cefalea usando anticuerpos anti-cgrp.
ECSP23044406A (es) Alimento para mejorar el rendimiento de un cultivo de decápodos
AR111837A1 (es) Plantas transgénicas inmunomoduladoras y métodos relacionados